Vol. 2, 783, April 1996 Clinical Cancer Research 783

Annual MeetingThe AACR’s Annual Meeting is one of the larg-est and most important annual gatherings of sci-enlists engaged in cancer research worldwide.The next Annual Meeting will take place in

Washington, D. C., from April 20-24, 1996. TheChairperson ofthe Annual Meeting is Lorraine J.Gudas of the Cornell University Medical Col-lege. Dr. Gudas and her Program Committeehave invited outstanding scientists in the field toorganize plenary sessions, symposia, methodsworkshops, controversy sessions, and meet-the-expert sunrise sessions. The Committee has just

completed the scheduling of proffered papers in

minisymposia, poster discussion sessions, and

poster sessions. The deadline for abstract sub-missions was December 1, 1995.

Workshop on Methods in Clinical

Cancer ResearchThis August the AACR and the American So-

ciety of Clinical Oncology (ASCO) will intro-

duce a new, 6-day summer workshop on din-

ical research methods designed for both

oncologists in training and senior investiga-

tors. The workshop will take place at the Inn atProspector Square in Park City, Utah, fromAugust 17-23, 1996. The overall goal of the

workshop will be to educate clinical scientistsin methods for clinical research and to encour-age better clinical trial design so that newcancer treatments can be introduced more rap-

idly into general medical practice. Major sup-

port for this program has already been ob-tamed from Bristol-Myers Squibb and Hoechst

Marion Roussel Amgen, and a grant proposalhas been submitted to the National CancerInstitute. Funds will be available to offset theregistration fees and housing and subsistence

expenses for 75 clinical trainees to attend the

workshop. In addition, 25 clinical investigatorsat the level of junior faculty will be accepted tothe workshop upon payment of a registration fee.(if additional funding is received, some travel

support may be available for junior faculty.)The Workshop Organizing Committee is

chaired by Drs. Daniel D. Von Hoff(for AACR)

and Charles A. Coltman, Jr. (for ASCO), both

of the Cancer Therapy and Research Center in

San Antonio, Texas. They will invite and se-lect a distinguished faculty that will deliver

over 20 hours of lectures on a variety of topicsin the field and direct four 2-hour small groupdiscussion sessions in which 25-30 partici-

pants will obtain practical training in subjects

that are essential to the success of clinical

trials. In addition, all participants will be re-sponsible for the preparation and submission

of a concept sheet for an actual clinical trialprotocol. Faculty will review and provide de-tailed critiques of these concept sheets. ASCO

AACRThe American Association for Cancer Re-

search (AACR) was founded in 1907 to bring

together active investigators of the cancerproblem for the presentation and discussion ofnew findings and to foster advances in cancer

research. Today the Association has more than

1 1,000 members working in all of the subdis-ciplines of cancer research in the United

States, Canada, and more than 50 other coun-

tries. Information on AACR programs and ad-

tivities can be obtained from

American Association forCancer Research

Public Ledger Building150 South Independence Mall West

Suite 816Philadelphia, PA 19106-3483

Phone: (215) 440-9300Fax: (215) 440-9313

The AACR welcomes applications for mem-

bership from the readership. Scientists en-gaged in all areas of cancer research are eligi-ble for membership. There are three categoriesof membership: active membership. open tocancer researchers working in the Americas;

corresponding membership, to those working

outside the Americas; and associate member-

ship, to graduate and medical students, post-doctoral fellows, and physicians-in-training.Further information on the qualifications foreach category as well as the benefits of mem-

bership can be found on the application forms

at the back of this issue.

will certify this workshop for Category 1 cred-

its toward the AMA Physicians RecognitionAward.

Information and application forms were

mailed to AACR and ASCO members in

March. Nonmembers should request brochuresfrom the AACR office. The deadline for re-ceipt of applications will be April 25, 1996.

AACR Special Conferences inCancer ResearchA number of meetings are now being orga-nized in the AACR’s new series of smaller

scientific meetings. Following are the topics,

dates, locations, and program committees for

some of these meetings. When full details of

each meeting are available, AACR members

will be the first to receive complete brochures

and application forms for participation in these

important conferences. Nonmembers may re-

ceive this information by sending their namesand addresses to Meetings Mailing List, Ameri-can Association for Cancer Research, Public

Ledger Building, 150 South Independence Mall

West, Suite 816, Philadelphia, PA 19106-3483.Telephone: (215) 440-9300. FAX: (215) 440-

9313. E-Mail: aacr@aol.com.

June 8-12, 1996

Inducible Genomic ResponsesChairpersons:

WILLIAM T. BECK, Memphis, TN

JOHN A. HICKMAN, Birmingham, EnglandRICHARD I. MORIMOTO, Evanston, ILSkamania Lodge, Stevenson (Columbia RiverGorge), WA

October 2-6, 1996

Novel Approaches in Blood and Marrow

Transplantation

Second Annual Meeting of the AmericanSociety for Blood and Marrow Transplantation

Chairpersons:

0. MICHAEL COLVIN, Durham, NCBRUCE R. BLAZAR, Minneapolis, MNHotel Del Coronado, San Diego, CA

October 19-23, 1996

Programmed Cell Death

Chairperson:

STANLEY J. KORSMEYER, St. Louis, MOThe Sagamore Resort, Bolton Landing

(Lake George), NY

January 10-14, 1997

Basic and Clinical Aspects of Lymphoma

Joint AACR/American Society of ClinicalOncology Conference

Chairpersons:

JOSEPH R. BERTINO, New York, NY

JAMES 0. ARMITAGE, Omaha, NEStouffer Renaissance Esmeralda Resort,Indian Wells (Palm Springs), CA

February 13-16, 1997

Growth Factors and CancerJoint Meeting with Australian Cancer SocietyChairpersons:

ANTONY BURGESS, Parkville, Victoria,AustraliaROBERT S. COFFEY, Nashville, TN

ASHLEY R. DUNN, Parkville, Victoria,Australia

RAYMOND L. WHITE, Salt Lake City, UTErskine House, Lorne, Victoria, Australia

February 23-27, 1997

Cell Signaling and Cancer Treatment

Conference Held in Collaboration with:

British Association for Cancer ResearchEuropean Organization for Research andTreatment of Cancer (PAMM Group)German Cancer SocietyAustrian Biochemical Society

Chairpersons:

HANS H. GRUNICKE, Innsbruck, AustriaGARTH POWIS, Tucson, AZPAUL WORKMAN, Macclesfield, EnglandCongress Center, Seefeld, Austria

�p_,4 AS��.1

$� �.

�R �

PROGRAM COMMITTEE

An Outstanding Opportunity for Researchers at the Level of Fellow or Junior Facultyto Learn The Essentials of Clinical Trials Design

THE AMERICAN ASSOCIATION FOR CANCER RESEARCHAND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

PRESENT

Methods in Clinical Cancer Research

August 17-23, 1996, Inn at Prospector Square, Park City, Utah

Supported by Generous Grants from Amgen, Inc., Bristol-Myers Squibb Oncology, and Hoechst Marion Roussel

Additional Support Pending from the National Cancer Institute

. A series of lectures by leaders in the field covering all elements of clinical trials design

S Small group discussion sessions on important techniques in clinical research

. Detailed critique of clinical trial protocol concept sheet developed by each participant

. Category I CME credits through ASCO

S Waiver of Registration Fees and Partial Travel Support for Oncology Fellows

. Extended Application Deadline: April 30, 1996

AACRDaniel D. Von Hoff, Chairperson

David S. Alberts

Gary M. Clark

Merrill J. Egorin

Sandra J. Horning

DAVID S. ALBERTS/ Tucson, AZOTIS W. BRAWLEY/ Bethesda, MD

GARY M. CLARK! San Antonio, TX

JERRY M. COLLINS! Rockville, MDCHARLES A. COLTMAN, JRJ San Antonio, TX

JOHN J. CROWLEY/ Seattle, WA

ROBERT T. DORRJ Tucson, AZ

JANICE P. DUTCHER! Bronx, NY

MERRILL J. EGORIN! Baltimore, MD

SUSAN S. ELLENBERG/ Rockville, MD

CHARLES K. GRIESHABER/ Rockville, MD

ASCOCharles A. Coltman, Jr. , Chairperson

Janice P. Dutcher

Michael A. Friedman

Steven Piantadosi

Mark J. Ratain

FACULTY

WAUN 1(1 HONG! Houston, TX

SANDRA J. HORNING! Palo Alto, CA

M. MARGARET KEMENYfManhasset, NY

ALBERT F. LOBUGLIOI Birmingham, AL

CAROL M. MOINPOUR! Seattle, WA

STEVEN PIANTADOSI/ Baltimore, MD

GINA P. PETRONI! Durham, NCMARK J. RATAIN! Chicago, IL

G. MARIE SWANSON! East Lansing, MI

IAN F. TANNOCK! Toronto, Ontario, Canada

DANIEL D. VON HOFF! San Antonio, TX

Additional Faculty To Be Announced

SESSION TOPICS

LecturesBasics of Phase I Clinical Trials

Design and Conduct of Phase II and III Clinical Trials

Ethics, Quality Assurance, and Recruitment

Special Clinical Trial Design Problems

Design of Trials of Preventive Agents

Small Group Discussions

Statistical Methods

Basic Clinical Pharmacology

Special Problems in Clinical Trial Design of Cytostatic Agents

New Measures of Outcome: Quality of Life and Clinical

Benefit

Further Information and Application Forms Available from

American Association for Cancer Research #{149}Public Ledger Building, Suite 816 #{149}150 S. Independence Mall West

Philadelphia, PA 19 106-3483 #{149}Telephone: (2 1 5) 440-9300 #{149}FAX: (2 1 5) 440-93 1 3 #{149}E-mail: aacr@aol.com

American Society of Clinical Oncology #{149}225 Reinekers Lane, Suite 650 #{149}Alexandria, VA 22314

Telephone: (703) 299-1070 #{149}FAX: (703) 299-1044 #{149}E-mail: kaminskm@asco.org

Clinical Cancer Research i

Instructions for Authors

Scope

Clinical Cancer Research, a journal of the American Associa-

tion for Cancer Research, publishes original articles describing

clinical research on the cellular and molecular characterization,

prevention, diagnosis, and therapy of human cancer. Its focus is

on innovative clinical research and translational research which

bridges the laboratory and the clinic. Clinical Cancer Research

is especially interested in clinical trials evaluating new treat-

ments for cancer; research on molecular abnormalities that pre-

dict incidence, response to therapy. and outcome; and laboratory

studies of new drugs and biological agents that will lead to

clinical trials in patients.

Specific areas of interest include clinical and translational

research in: molecular pharmacology and chemotherapy; drug

sensitivity and resistance; tumor immunology and immunother-

apy; radiobiology and radiation oncology; solid tumor oncol-

ogy; hematological malignancies: surgical oncology: pediatric

oncology; molecular oncology and cancer genes: pathology,

markers, and prognostic indicators; growth factors, cytokines,

and signal transduction; bone marrow transplantation; gene ther-

apy; cancer endocrinology; cell adhesion, invasion, and metas-

tasis; prevention of primary and recurrent cancer; differentiation

and cell death; clinical genetics; and detection of minimal dis-

ease.

Editorial Policy

When a manuscript is received for consideration, the Editors

assume that no similar paper has been or will be submitted for

publication elsewhere. Further, it is understood that all authors

listed on a manuscript have agreed to its submission. The

signature of the corresponding author on the letter of submission

signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, and Asso-

ciate Editors reveal in a letter to the Editor-in-Chief any rela-

tionships that they have that could be construed as causing a

conflict of interest with regard to a manuscript under review.

The letter should include a statement of any financial relation-

ships with commercial companies involved with a product under

study.

Upon acceptance, authors must transfer copyright to the

American Association for Cancer Research, Inc., the copyright

owner of the journal, prior to publication. The Editors endorse

the principles embodied in the Declaration of Helsinki and

expect that all investigations involving humans will have been

performed in accordance with these principles. To obtain a copy

of the Helsinki Declaration, please contact the World Medical

Association, 28, Ave. des Alpes, F-0l210, Ferney-Voltaire,

France. For animal experimentation reported in the journal, it is

expected that investigators will have observed the Interdisciplin-

ary Principles and Guidelines for the Use of Animals in Re-

search, Testing, and Education issued by the New York Acad-

emy of Sciences’ Ad Hoc Committee on Animal Research, a

copy of which is available for $5.00 from the Marketing De-

partment, New York Academy of Sciences, 2 East 63rd Street,

New York, NY 1002 1-7289. All human and animal studies must

have been approved by the investigator’s Institutional Review

Board.

Review Process

The review process. expedited by fax transmission and over-

night mail service, is conducted as rapidly as possible. Each

submitted manuscript is reviewed by at least two experts in the

field of investigation. If the authors are invited to submit a

revised manuscript for an expedited further review, the revised

version must be submitted within three months.

Manuscript Submission

Send manuscripts to John Mendelsohn, M.D., Editor-in-Chief,

Clinical Cancer Research, at Department of Medicine, Memo-

rial Sloan-Kettering Cancer Center, 1275 York Avenue, New

York, NY 10021. Submit four original sets (not photocopies) of

figures along with four copies of the manuscript. If a manuscript

is closely related to papers that are in press or have been

submitted elsewhere. please provide copies of those papers with

your submission.

Advances in Brief will be reserved for concise, definitive

reports of novel observations and discoveries that have unusual

importance. A request for consideration for Advances in Brief

should be included in the letter of submission. A Minireview is

a brief analysis (typically 3-4 printed pages) of a focused, timely

research topic, aimed at a multidisciplinary audience. Minire-

views and Controversies in Clinical Cancer Research that are

submitted or solicited will undergo editorial review. The Editors

welcome Letters to the Editor, which will be published if they

are determined to be appropriate.

The letter of submission should suggest the Associate

Editor (or Editor-in-Chief) who will serve as primary reviewer

of the manuscript. In addition, we invite authors to provide the

names, addresses, and telephone/fax numbers of up to five

potential reviewers who are not current or recent collaborators

or advisors in the area under investigation.

For both original and revised submissions, we cannot guar-

antee that manuscripts and illustrations will be returned to the

author.

Format

Manuscripts must be written succinctly in clear, grammatical

English. Define abbreviations in an inclusive footnote to the

text. Double-space on 8 1/2 x 1 1-inch paper. Dot-matrix printing

is not acceptable. The format is as follows:

I . Title page, including title, authors and their institutions,

research support, and address plus telephone/fax numbers of

the corresponding author;

2. A running title of fewer than 50 characters;

3. Three to five key words that do not appear in the title;

4. Abstract, of not more than 250 words, stating briefly the

objectives, methods, results, and conclusions of the study:

5. Text arranged in this order: Introduction, Methods, Results,

Discussion, Acknowledgments, References;

ii Instructions for Authors

6. Footnotes, on a page separate from the text. Designate foot-

notes consecutively with superscript Arabic numerals;

7. Tables, on pages separate from the text, with descriptive

titles and legends that make the data understandable without

reference to the text;

8. Figure legends, on pages separate from the text, with descrip-

tive titles and explanations to make the data understandable

without reference to the text. Define all symbols and include

staining for halftones where applicable;

9. Figures.

the author requests a greater width. Use tissue overlays to

indicate important areas of the photographs that must be repro-

duced with greater fidelity.

Authors are encouraged to submit color figures. The ex-

pense of reproducing color photographs must be offset partially

by the author. In 1996, the cost of color reproduction charged to

authors will be $975 per color figure. Submit color figures on

flexible backing.

Proofs

References

Include only those articles that have been published or are in

press. Unpublished data or personal communications must be

cited as footnotes to the text. Personal communications should

be substantiated by a letter of permission. Number references in

the order of their first mention in the text. Cite only the number

assigned to the reference. References must be double-spaced.

Page proofs must be returned to the office of the American

Association for Cancer Research within 24 hours of receipt.

Return proofs by overnight mail. Proofs not received by the

deadline will be published without the authors’ corrections.

Accepted manuscripts are regarded as final copy and should not

be altered substantially in proof. Extensive alterations could

cause publication delays, and authors will be charged for exces-

sive alterations in proof.

SAMPLE REFERENCES:

1. Shaffer, D. W., Smith, L. S., Burns, H. A., Clark, G. M., Eckardt,J. R., Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn,

J. G., and Von Hoff, D. D. A randomized phase I trial of chronic oraletoposide with or without granulocyte-macrophage colony-stimulating

factor in patients with advanced malignancies. Cancer Res., 53: 5929-

5933, 1993.

2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal

antibody therapy of cancer. In: H. M. Pinedo, B. A. Chabner, and D. L.

Longo (eds.), Cancer Chemotherapy and Biological Response ModifiersAnnual, Vol. 11, pp. 177-203. Amsterdam: Elsevier Science Publishers

B. V., 1990.

Figures

Provide four original sets of figures (whether line-cut draw-

ings or halftones). Each sorted set should be in a separate

labeled envelope, for distribution to reviewers. A typed label

placed on the reverse side of each figure should contain the

first author’s name, figure number, and an arrow indicating

top of figure. Letters and numbers on figures should not be

smaller than 6-point or larger than 12-point type. All figures will

be published at a width of approximately 3 inches (8 cm) unless

Typesetting Manuscripts from Computer Disks

Clinical Cancer Research welcomes disks to expedite produc-

tion of accepted manuscripts. If your article is accepted for

publication, you will receive instructions regarding disk submis-

sion. It is the author’s responsibility to ensure that the material

on the disk matches the final accepted version of the manuscript.

For more information, contact:

John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Re-

search, Department of Medicine, Memorial Sloan-Keuering

Cancer Center, 1275 York Avenue, New York, NY 10021,

Telephone 212-639-6317, Fax 212-717-3629

or:

Publications Department, American Association for Cancer Re-

search, Public Ledger Building, Suite 816, 150 South Indepen-

dence Mall West, Philadelphia, PA 19106-3483, Telephone

215-440-9300, Fax 215-440-9355.

BENEFITS OF MEMBERSHIP

Notification of Candidate

MarchJulyNovember

AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ACTIVE AND

CORRESPONDING MEMBERSHIP

The American Association for Cancer Research (AACR), a scientificsociety of over I 1 .000 laboratory and clinical cancer researchers, was

founded in 1907 to facilitate communication and dissemination of knowl-edge among scientists and others dedicated to the cancer problem; tofoster research in cancer and related biomedical sciences; to encourage thepresentation and discussion of new and important observations in thefield; to foster public education, science education, and training; and toadvance the understanding of cancer etiology, prevention, diagnosis, andtreatment throughout the world.

Members of the AACR enjoy the following benefits:

1 . the privilege of sponsoring a proffered paper (abstract) for consider-ation for presentation at the AACR annual meeting;

2. an advance copy of the Program and Proceedings of the American

Association for Cancer Research that contains over 4,000 abstracts of

proffered papers presented at the annual meeting;

3. reduced registration rates at annual meetings;

4. priority notice of small, focussed meetings in the AACR’s excitingseries of Special Conferences in Cancer Research;

5. substantially reduced registration rates for Special Conferences;

6. opportunities for participation in AACR meetings in North Americaand abroad with other scientific societies around the world;

7. receipt of AACR Newsletters and other important announcements;8. early notification of and reduced rates for participation in the AACR

Employment Register;

9. an up-to-date Membership Directory of over 1 1 ,000 member re-searchers in the cancer field;

10. the professional benefits of the AACR’s public education activitiesconcerning funding for cancer research and press coverage of thelatest research findings;

1 1 . the opportunity to participate in three Summer Workshops that fosterknowledge in the cancer field for young investigators;

12. the facilitation of informal scientific exchange with leading research-

ers in the cancer field; and13. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in

the Americas. Individuals who have conducted two years of researchresulting in peer-reviewed publications relevant to cancer, or who have

made substantial contributions to cancer research in an administrative oreducational capacity, are eligible. If a candidate has conducted research in

an area of biomedical science related to cancer, he or she will qualify formembership. Evidence of patents relevant to cancer research may be

submitted as qualifications for membership in lieu of peer-reviewed

publications.

Corresponding membership is open to persons who are not residents

of the Americas. The qualifications for corresponding membership are thesame as those indicated above for active membership. Visiting scientistsfrom outside the Americas who intend to return to their countries of originby the anticipated time of election should apply for corresponding mem-

bership. All other visiting scientists should apply for active membershipand transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in

training who do not yet meet the above qualifications for active orcorresponding membership should apply for associate membership.

Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application:January 1, May 1, and September 1 of each year. The MembershipCommittee will review all complete applications for active membershipthat have been received by these deadlines and will submit recommenda-tions on each candidate to the Board of Directors which formally elects allmembers. The same procedure is followed by the Special Memberships

Committee which receives applications for corresponding membership.Candidates will be notified according to the following schedule:

Receipt of Applicationin AACR Office ________________

January 1May 1September 1

A complete application consists of the following material:1. 6 copies of the form on the opposite side of this page, with all requested

information provided.

2. 5 copies of the candidate’s most current curriculum vitae and bibliog-

raphy.3. 5 copies of a letter of recommendation from a nominator who is an

active, corresponding, emeritus, or honorary member of the AACR (at

least one copy must be a signed, original letter). This letter shoulddescribe the candidate’s achievements in laboratory research, clinicalinvestigations. or epidemiological research, and it should affirm that

this research adheres to accepted ethical scientific standards. -OR- The

nominator may supply the responses requested at the bottom of theapplication form in the section entitled “STATEMENT OF SUP-PORT” (at least one copy of the form must be the signed original).

4. 5 copies of a letter of recommendation as described in Item 3 above

from a seconder who is an active, corresponding, emeritus, or honorary

member of the AACR (at least one copy must be a signed, originalletter). -OR- The seconder may supply the responses requested at thebottom of the application form in the section entitled “STATEMENT OFSUPPORT” (at least one copy of the form must be the signed original).

5. 5 reprints of each of two publications on which the candidate appears asauthor. As noted above, evidence of patents developed by the candidate

may be submitted in lieu of one or both of the publications. If submittingpatents, supply patent number and year awarded.

All material should be collated into five complete sets with the originalapplication form as a covering document and sent to the address givenbelow. Questions regarding procedures for membership application mayalso be directed to the following address:

American Association for Cancer ResearchPublic Ledger Building, Suite 816

150 5. Independence Mall West

Philadelphia, PA 19106-3483

Phone: 215/440-9300FAX: 215/440-9313

E-mail: aacr@aol.com

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of mem-bership in the AACR. Active members must pay annual dues. In 1996annual dues for active members are $ 160, $95 of which is designated forAACR journal subscriptions. Newly elected members of the AACR whohave already purchased subscriptions to Cancer Research, Clinical Can-

cer Research, Cell Growth & Differentiation, or Cancer Epidemiology,

Biomarkers & Prevention at the higher, nonmember rates will receivereimbursement of the unused portion of those subscriptions once their first

year’s membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1996) and

may, if they wish, subscribe to Cancer Research, Clinical Cancer Re-

search, Cell Growth & Differentiation, or Cancer Epidemiology, Biomar-

kers & Prevention at reduced member rates.Applicants elected in March will be responsible for payment of that

year’s dues; applicants elected in July and November will pay dues for thefollowing year. Applicants elected in March and July will be eligible tosponsor an abstract for the next annual meeting. Every effort will be made

to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.Executive Director

LAST FIRST

PMI.

DATE OF BIRTH:__________

(Please print)

n CORRESPONDING MEMBERSHIP

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

(This form may be reproduced.) I 996

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.Public Ledger Building . Suite 816 . 150 S. Independence Mall West . Philadelphia, PA 19106-3483

NAME OF CANDIDATE:

APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

PRESENT POSlTIONR’ITLE:.�

INSTITUTIONAL AFFILIATION:

INSTITUTIONAL ADDRESS:�

(City) (State/Province)

TELEPHONE NUMBER:______________________________

(Country) (Postal Code)

FAX NUMBER:__________________________

E-MAIL NUMBER

PRIMARY FIELD OF RESEARCH (Please check only one):

(CARRIER):________________________________________

Biochemistry and Biophysics Biostatistics Carcinogenesis

Biology and Genetics Investigations Endocrinology

Epidemiology Immunology Biology and Genetics

Pharmacology and Virology

Experimental Therapeutics

Other:____________________________________

(Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list m ost recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For

these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent

number and year awarded.)

CANDIDATE

NOMINATED BY*:

(Please print)

CANDIDATE IS APPLYING FOR (Check one): � ACTiVE

How long has the candidate worked in the field of cancer re-

search? years

Will the candidate make a long-term contribution to cancer re-

search? Yes .........�No

Does the candidate’s research adhere to accepted ethical stan-

dards? ..Yes ..No

I therefore recommend this candidate for membership in the American

Association for Cancer Research.

CANDIDATE

SECONDED BY*:

How long has the candidate worked in the field of cancer re-

search? years

Will the candidate make a long-term contribution to cancer re-

search? ............Yes ..No

Does the candidate’s research adhere to accepted ethical stan-

dards? ....Yes .........NoI therefore recommend this candidate for membership in the American

Association for Cancer Research.

Signature of nominator* Date Signature of seconder* Date

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active. corresponding. emeritus, or honorary members of the AACR.

AMERICAN ASSOCIATION FOR CANCER RESEARCH

� GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSH�]

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students,

postdoctoral fellows, and physicians in training who are following acourse of study or who are working in a research program relevant to

cancer. Scientists in training who already have a substantial record of

publications may wish to apply for active or corresponding membership

which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientificsociety consisting of laboratory and clinical cancer researchers, was

founded in 1907 to facilitate communication and dissemination of knowl-edge among scientists and others dedicated to the cancer problem; tofoster research in cancer and related biomedical sciences; to encourage

presentation and discussion of new and important observations in the

field; to foster public education, science education, and training: and toadvance the understanding of cancer etiology, prevention. diagnosis. andtreatment throughout the world. Associate members of the AACR enjoythe following benefits:

1 . the privilege of sponsoring a proffered paper (abstract) for consider-ation for presentation at the AACR annual meeting provided that (a)

the associate member is the presenter of the paper and (b) an active,corresponding, emeritus, or honorary member in good standing of the

AACR also signs the abstract of the paper in support of the work. (In

this instance, the member who cosigns the abstract does not lose his

or her own sponsorship privilege.):2. an advance copy of the scientific Program and (if one has been

purchased by the associate member) the Proceedings ofthe American

Associationfor Cancer Research that contains over 4,000 abstracts of

proffered papers presented at the annual meeting;3. the privilege of registering for the annual meeting at the low associate

member rate;

4. preferred access to the AACR Employment Register:

5. optional subscriptions to the Association’s high-quality journals Can-

cer Research, Clinical Cancer Research, Cell Growth & Differenti-

ation, and Cancer Epidemiology, Biomarkers & Prevention at re-

duced member rates:6. priority notification of events in the AACR’s series of special con-

ferences on timely subjects in the field;

7. substantially reduced registration rates at special conferences;

8. the receipt of AACR newsletters. meeting announcements, and anup-to-date Membership Directory:

9. the opportunity to participate in three Summer Workshops that fosterknowledge in the cancer field for young investigators: and

10. the facilitation of informal scientific exchange with leading research-

ers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use theofficial application form on the reverse side of these instructions. Each

candidate for associate membership must be nominated by an active,

corresponding, emeritus, or honorary member in good standing of the

AACR. Three completed copies of the form should be submitted; at least

one of these copies must carry the original signatures of both the candidateand the nominator. The application form may be submitted to the Asso-

ciation Office at any time.

After review of applications for associate membership, the Executive

Director will notify candidates of their election or deferral within one

month of the receipt of the application form. A check for one year’s duespayment must accompany the application. Dues are currently $35 forassociate members residing in the Americas and $45 for residents of other

countries. This fee will be refunded to any candidate deemed to be

ineligible for associate membership. Checks should be in U.S. currency,

made payable to AACR, Inc., and drawn on a U.S. bank. Send the three

copies of the application form and the $35 or $45 dues payment to:

American Association for Cancer ResearchPublic Ledger Building, Suite 816

150 5. Independence Mall West

Philadelphia. PA 19106-3483

Phone: 215/440-9300FAX: 215/440-9313

E-mail: aacr@aol.com

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be deter-

mined by the AACR Board of Directors. Dues for 1995 and 1996 have

been set at $35 per year for residents of the Americas and $45 for residents

of other countries. If an application is submitted by August 3 1, theaccompanying dues payment will be credited to the current year. Candi-

dates submitting applications between September 1 and December 3 1 may

indicate whether they wish their dues payments credited to the current or

forthcoming year. Candidates should be aware, however, that associate

members may sponsor an abstract for the annual meeting only if their duesfor the current year are paid. For example, an associate member submit-

ting an abstract in November 1995 for the forthcoming annual meeting

must have paid dues for 1995. Any newly elected associate members of

the AACR who have already purchased subscriptions to (‘ancer Research.

Clinical Cancer Research, Cell Grrnt’thi & Differentiation, or (‘ancer

Epidemiology, Biomarkers & Prevention at the higher. nonmember rate

will receive a refund for the unused portion of that subscription upon

receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoicefor dues for the forthcoming year. Payment of this invoice must beaccompanied by a statement signed by the associate member’s current

registrar, dean, or department head. verifying the member’s current aca-

demic status. The Association’s By-Laws state that dues are payable for

each year in advance by January 1 of the year to which they should be

applied. An individual may be an associate member for a maximum of

five years. Each year in which an individual pays dues will count as onefull year of associate membership. Thus, an associate member who paysdues for 1995 may retain associate membership until December 3 1, 1999.

The Board of Directors may terminate the membership of an associatemember whose dues are in arrears for two years.

Margaret Foti, Ph.D.

Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.Public Ledger Building � Suite 816 . 150 S. Independence Mall West . Philadelphia, PA 19106-3483

APPLICATION FOR

NAME OF CANDIDATE:________________________________________

LAST FIRST

ASSOCIATE MEMBERSHIP

DATE OF BIRTH:__________

MI.

INSTITUTIONAL

INSTITUTIONAL ADDRESS:

AFFILIATION:_________________________________________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER:______________________________ FAX NUMBER:__________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER):

______Graduate Student ______Medical Student

Physician in Training Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

Biochemistry and Biophysics Biostatistics Carcinogenesis

______Cellular Biology and Genetics ______Clinical Investigations Endocrinology

Epidemiology Immunology Molecular Biology and Genetics

______Preclinical Pharmacology and Virology Other:____________________________________

Experimental Therapeutics (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide

information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal. volume, inclusive pages, and year of any article in a peer-reviewed journal on which the

candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY*:_____________________________________________________________

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of

this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are

true.

Signature of Candidate:__________________________________________________________________ ___________________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge. the

candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*:___________________________________________________________________ ____________________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check

in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. Dues are currently $35 for associate members

residing in the Americas and $45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the E current � forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor

an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this

form for further instructions.

*Nomjnator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.) 1996

Guidelines for Submitting Disksto

American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite WordPerfect (DOS, Windows,Microsoft Word (DOS, Windows, and Macintosh)

and Macintosh) XyWrite (DOS and Windows)

Also acceptable:

Ability Mass 1 1 SoloWriterAmiPro MS Windows Write SprintAM S-T�X MS Works StxAppleworks MS Works WP Mac SunWriteArborT�X Multimate SymphonyArborText Multimate Advantage TEXClarisWorks WP Nibia TaX78CPT 8000 Nisus (to ASCII file) Text EXecutiveCTOS Notewriter TexturesDiablo Obun Total WordDisplayWrite OfficeWriter TroffDuet PC WriteEinstein PFS First Choice VolkswriterEnable Professional Write VuWriterEXP Q&A Write Wang 015Final Word Quark XPress Wang WPSFullWrite RagTime MS Works Wang WriterGemWord Plus (to ASCII file) Window WorksIBM Writing Assistant Rich Text Format Windows WriteInterleaf RSG (to ASCII file) WiziWordLATEX Signature WordstarLatex SLIT�X Wordstar 2000Leading Edge SmartWhere WriteNowLotus Manuscript SmartWrite II XeroxLotus Write

Software packages that we are unable to translate:

FrameMaker Ready, Set, GoPageMaker Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple orWang computers can also be converted. Because of the file structures and internal coding, we cannot accept

disks created on desktop publishing systems or those created on proprietary typesethng systems. We alsocannot guarantee that all special characters can be translated. Tabular and mathematical material, such asequations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the diskfile. The tables and equations will be keyed from this hard copy. We also need to know the name of the fileto be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system(e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK.

DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.

DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. Whensubmitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along withthe required four hard copy printouts. Disks will ultimately be returned to the authors.

I See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the mostrecently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathe-matical and tabular material, however, will be processed in the traditional manner and may be excluded fromthe disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly releasedsoftware, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of themanuscript, and the name of the computer file used to access the manuscript on disk. To process your diskefficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: _____________________

Name of computer used (e.g., IBM/PS2):

Operating system and version (e.g., DOS 3.3):

Word processing program and version (e.g., WordPerfect 5.0):

[See reverse for acceptable programs.]

Manuscript number: __________________________________

First author: __________________________________________

Corresponding author (if different from first author):

Telephone/FAX numbers: ____________________________

This form (both sides) may be reproduced.

ClinicalCancerResearch

COtJNTRY

ORDER TODAY!

Don’t miss a single issue of the latest clinical and translational research!

An official journal of the American Association for Cancer Research

ORDER FORM: Yes! I’d like to subscribe!

A Monthly Journalfeaturing the most innovative

clinical research and

translational research bridging

the laboratory and the clinic.

Editor-in-Chief

John Mendelsohn,M.D.Memorial Sloan-Kettering Cancer

Center

Subscribe Now!Every issue is essential

reading.

Call 1-800-875-2997

or 201-627-2427,

or mail back the attached

order card.

No-Risk Guarantee:If you are not entirely

satisfied with this journal,

you will receive a refund

for any unmailed issues

on your subscription.

Clinical Cancer Research

Vol.2, 1996, 12 issues,ISSN 1078-0432

Institutional (Available only as a combined subscription

with Cancer Research)

LI $595U $130 should be added for delivery outside the U.S.

Individual

D$95

El $40 should be added for delivery outside the U.S.

AACR Members: Contact theAACR for rates, (215) 440-9300.

Canada: Add 7% GST. MD: Add state sales tax.

Individual Subscriber: I certify that this

subscription is solely for my personal use and will not be

used in a library.

SIGNATURE

NAME

ADDRESS

CItY, STATE. ZII’

COUNTRY

ORDER FORM: Yes! Id like to subscribe!

Clinical Cancer Research

Vol. 2, 1996, 12 issues, ISSN 10780432

Institutional (Available only as a combined subscription

with Cancer Racearth)

D$595

D $130 should be added for delivery outside the U.S.

Individual

D$95LI $40 should be added for delivery outside the U.S.

AACR Members: Contact the MCR for rates, (215) 440-9300.

Canada: Add 7% GST. MD: Add state sales tax.

Individual Subscriber I certify that this

subscription is solely for my personal use and will not be

used in a library.

SIGNATURE

Method of Payment

� Enclosed check or money order in U.S. dollars drawn

on U.S. bank. Payable to American Association for

Cancer Research.

E Institutional purchase order #________________is enclosed

E Please charge my D Mastercard El VISA

� American Express

ACCOUNT NAME

ACCOUNT NO.

EXPIRATION DATE

SIGNA11�RE

U Please send me InstrucfionsforAulhors.

Method of Payment

LI Enclosed check or nioney order in U.S. dollars drawn

on U.S. bank. Payable to American Association for

Cancer Research.

LI Institutional purchase order #________________is enclosed

LI Please charge my LI Mastercard LI VISA

LI American Express

ACCOUNT NAME

A(:(:OUNr NO.

EXPIRATION I)ATE

sI(;NA11 IRE

NAME

ADI)RESS

CITY. STATE. ZIP

El Please send me Instruction.sfor Authors.

ClinicalCancerResearch

�n official journal of the American Association for Cancer Research

H��U NO POSTAGE

NECESSARY

IF MAILEDIN THE

UNITED STATES

I �

� � �

NO POSTAGE

NECESSARYIF MAILEDIN THE

UNITED STATES

I I I � � . I. . . II.� I...I I . . I . . II� I .. . i I I .� I. I #{149}I #{149}I #{149}#{149}#{149}#{149}1.11

Order This Important New Journal Today!

BUSINESS REPLY MAILFIRST CLASS PERMIT NO. 724 EASTON, MD

POSTAGE WILL BE PAID BY ADDRESSEE

CLINICAL CANCER RESEARCHP0 BOX 3000DENVILLE NJ 07834-9359

BUSINESS REPLY MAILFIRST CLASS PERMIT NO. 724 EASTON. MD

POSTAGE WILL BE PAID BY ADDRESSEE

CLINICAL CANCER RESEARCHP0 BOX 3000DENVILLE NJ 07834-9359

A Monthly Journalfeaturing the most innovative

clinical research and

translational research bridging

the laboratory and the clinic.

Editor-in-Chief

John Mendelsohn,M.D.Memorial Sloan-Kettering Cancer

Center

Subscribe Now!Every issue is essential

reading.

Call 1-800-875-2997

or 201-627-2427,

or mail back the attached

order card.

No-Risk Guarantee:If you are not entirely

satisfied with this journal,

you will receive a refund

for any unmailed issues

On your subscription.

AMERICAN ASSOCIATION FOR

CANCER RESEARCH

The American Association for Cancer Research

(AACR) is a professional society of over 11,000scientists and physicians involved in all aspects of

basic, clinical, and translational cancer research.

Members of the AACR enjoy

. subscriptions to Cancer Research, Cell Growth &

Differentiation (CG&D), Cancer Epidemiology,

Biomarkers & Prevention, and Clinical Cancer

Research at reduced member rates

. reduced registration rates at the AACR Annual

Meeting, Special Conferences, and International

Meetings

. Employment Register, Directory of Members,

public education activities, and many other

benefits

Special programs to provide enhanced career devel-

opment opportunities for minority scientists include

. Session on Career Development at Annual

Meeting

. Mentorship Program

. Travel Awards to Scientific Meetings

American Association for Cancer Research

Public Ledger Building, Suite 816

150 S. Independence Mall West

Philadelphia, PA 19106-3483

Telephone: (215) 440-9300

FAX: (215) 440-9313 I E-Mail: aacr@aol.com

MAYO CLINIC

DIVISION OF MEDICAL ONCOLOGY

AND MAYO CANCER CENTER

Clinical Research Positions

The Division of Medical Oncology and the NCI-designated

Mayo Cancer Center in Rochester. Minnesota. invite applica-tions for two clinical research positions. Clinical investigatorswith established cancer research programs are encouraged to

apply. The Mayo Clinic provides an outstanding environment

for investigators interested in conducting translational researchwith the goal of improving prevention. diagnosis. and treat-

ment of cancer. Interested applicants should submit a statement

of research interests, curriculum vitae, bibliography. and list of

references to:James N. Ingle, M.D.

Associate Director for Clinical ResearchMayo Cancer Center

Mayo Clinic

200 First Street. SW

Rochester, MN 55905

PVkIV() Foundaiioui is’ (lfl ciJJir�naf�te ciefloul (1,1(1ecjiialO/)j)OrtlI!litv ec/uIc(ltor (l?ll! #{163}‘Fnplover.

THE SURGERY BRANCI-l, NATIONAL CANCER INSTITUTE, NIH, IS SEEKING FATIENTS FOR

ONGOING CLI N ICAL TREATM ENT I’ROGRAMS.

PATIENTS WITH TIlE FOLLOWING MALIGNANCIES ARE BEING TREATED UNDER COMBINED

MODAI.ITY OR I N NOVATIVE IMMU NOTH ERAFY FROGRAMS:

. METASTATIC MELANOMA AND KIDNEY CANCERS

. STAGE II OR LOCALLY ADVANCED BREAST CANCER#{149}

. METASTATIC COLORECTAL CANCER TO THE I.IVER.

. LOCOREGIONAL GASTRIC OR I�ANCREATIC CANCER .

. MESOTHELIOMA, PULMONARY METASTASES, STAGE lIlA, B 1.UNG CANCER

OR ESOPHAGEAL CANCERS

. LOCALIZED SOFT TISSUE SARCOMAS.

. PERITON [A L CA RCINOMATOSIS#{149}

NI��flONALI ( ANCER

INSTITUTE

CARE FOR ALL I’ATIENTS IS I�R()VIDED AT THE CLINICAl. CENTER, NIH,

BETHESDA, MARYLAND.

FOR MORE INFORMATION ON CANCER PROGRAMS, I’LEASE CALL

(301) 496-1533

.1 Pi i�i i� .�i RI I( I A.\ \ ( 11 ,\ ( /�,II/ ,\ I (.‘( )( k I I � } ( )/ I I/Is P1 III 1 . � I f( ),\

ONCt�.GY�*NtU�: �

The� ne,& adv2flcein �an�,er care.Please visit us at Island #452

,... I

MEDICAL LIBRARIAN

Our search eiigiiie is ro ughly 17,000 times faster

than the one you’ve probably beeii usiii�.

. \flj. j�ll’� \\‘� S�1\’. JUSt �s 11�i�IlJI\.

TntrHuciii� I1C�l�\’ �I1lifl�.

� h� � iit�i’n�t s�-vcc h�o �iv�s

�1S\’, 1I11fl1�JL1t� �1CC�SS t� EhC

ni�st C�111prCI1�I1S1\’� S�UUCC

p Ii�i i- tii �t c� U t i C�t I. � I� n I C�1 I � n J

� I1�I’�1)�U t� C iflL�iili�ii k�n . \\� t Ii�ut

1�l\’1t1� k� I�t\’C \�ur �1fic�.

11C�I�\’ c�ii1iii� h�’iii�s \�U

uiii’�stiictcJ �icccss t� \\I! �I NF

� RI � � , 1�I � . .\1 I �I Ni �iiiJ

11.\! �1 I � . 1�lus a luIl-tcxt Iihrarv �1

LN1 CC�I�\’ jC�U Ull �11S �U1J U�- tC� -J�it

�I1CC�l�V aiiJ tii�Jj��d nc\vs.

.\tii \‘�U caii s�irch thc�m all in

pk�i ii F Ih�!isl1, n�t cc�iiiput�r Iangua�.

( �)nc�lc�s�v OiiI�ti� �Is� �iv�s \‘�U

sccu i.� , ph ys i ci a ii - � n Iy access t

int�t-�ictiv� ft�runis in �iII caiic�i’

S U Ks N1 � � � I �S , Ci\\ 1 s � iii i ii � U

listings �iiiJ 1ic�tIinks tc� �v�r

Ioc� 1i1#{188}�JicaI sch�I �nJ

c�It1c�r C�iitCi Sit�S \‘RI tIi� Tntcriict.

\\Tith Oiic�lc�g�� Onhn�. th� Jat�

\‘�U Il�J IS t1i�r� ii�ht iic�w.

\lt�r �1I, sp�tiJi1i� L�ss time in th�

I i bU�U\’ � ust 11 � �JJ ti Ill � \\‘l1�UC it

r�atI\’ CL�UtitS.

.:.Ours is �i ir� S�1�\’iC�. Th 1� �n

ininJi�t�Iv: http: ni�Js�rv.c�ni

�r call I.�OO.�()5.4()7Q �itiJ hnd �ut

Ii�\v tC� �Ct

�N1I1I1� List.